Autoantibodies and High-Risk HLA Susceptibility Markers in First-Degree Relatives of Brazilian Patients with Type 1 Diabetes Mellitus: A Progression to Disease Based Study


Autoria(s): Alves, L. I.; Davini, E.; Correia, M. R.; Fukui, R. T.; Santos, R. F.; Cunha, M. R.; Rocha, D. M.; Volpini, W. M. G.; Silva, M. E. R.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

01/11/2013

01/11/2013

2012

Resumo

The objective of this study was to determine the frequencies of autoantibodies to heterogeneous islet-cell cytoplasmic antigens (ICA), glutamic acid decarboxylase(65) (GAD(65)A), insulinoma-associated antigen-2 (IA-2A) and insulin (IAA)-and human leukocyte antigen (HLA) class II markers (HLA-DR and -DQ) in first degree relatives of heterogeneous Brazilian patients with type I diabetes(T1DM). A major focus of this study was to determine the influence of age, gender, proband characteristics and ancestry on the prevalence of autoantibodies and HLA-DR and -DQ alleles on disease progression and genetic predisposition to T1DM among the first-degree relatives. IAA, ICA, GAD(65)A, IA-2A and HLA- class II alleles were determined in 546 first-degree-relatives, 244 siblings, 55 offspring and 233 parents of 178 Brazilian patients with T1DM. Overall, 8.9% of the relatives were positive for one or more autoantibodies. IAA was the only antibody detected in parents. GAD(65) was the most prevalent antibody in offspring and siblings as compared to parents and it was the sole antibody detected in offspring. Five siblings were positive for the IA-2 antibody. A significant number (62.1%) of siblings had 1 or 2 high risk HLA haplotypes. During a 4-year follow-up study, 5 siblings (expressing HLA-DR3 or -DR4 alleles) and 1 offspring positive for GAD(65)A progressed to diabetes. The data indicated that the GAD(65) and IA-2 antibodies were the strongest predictors of T1DM in our study population. The high risk HLA haplotypes alone were not predictive of progression to overt diabetes.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Identificador

JOURNAL OF CLINICAL IMMUNOLOGY, NEW YORK, v. 32, n. 4, supl. 4, Part 1, pp. 778-785, AUG, 2012

0271-9142

http://www.producao.usp.br/handle/BDPI/37703

10.1007/s10875-012-9673-4

http://dx.doi.org/10.1007/s10875-012-9673-4

Idioma(s)

eng

Publicador

SPRINGER/PLENUM PUBLISHERS

NEW YORK

Relação

JOURNAL OF CLINICAL IMMUNOLOGY

Direitos

closedAccess

Copyright SPRINGER/PLENUM PUBLISHERS

Palavras-Chave #TYPE I DIABETES #AUTOANTIBODIES #HLA-DR/DQ #GAD65A #IAA #IA2-A #ISLET-CELL ANTIBODIES #INSULIN AUTOANTIBODIES #IDDM #AGE #IA-2 #FAMILY #ONSET #DECARBOXYLASE #PATHOGENESIS #EXPRESSION #IMMUNOLOGY
Tipo

article

original article

publishedVersion